Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2005

View Archived Issues

Xcytrin with radiosurgery studied in phase II trial for brain metastases

Multi-party collaboration to develop treatments for spinal injury, neurotrauma

NexMed licenses NM-100060 for onychomycosis to Novartis

NicOx and Ferrer expand agreement in dermatology

Preliminary phase I data on VX-001 immunotherapy in cancer patients

Antidiabetic potential of RWJ-348260 evident in preclinical models

(-)-Oleocanthal, a compound in extra-virgin olive oil with ibuprofen-like activity

Preclinical profile and efficacy of CK-1827452 in a model of heart failure

Pharmacokinetics of oral insulin analogue IN-105 resemble those of insulin

KOS-2187: Novel motilide chosen as a clinical candidate

Novel NS5B polymerase inhibitor with in vitro efficacy and in vivo bioavailability

New efforts in avian flu vaccine development

Ziopharm and Easyweb complete merger

Hana Biosciences: pipeline progress

EntreMed enters CRADA with NCI to study HIF-1alpha inhibition in cancer

Cholesterol absorption inhibitor MD-0727 enters phase I testing

Prostaglandin F2alpha antagonist THG-113.31 delays preterm birth in sheep

Interim results for phase II study of Campath in MS

Affiris reports positive preclinical findings for Alzheimer's vaccine

rhGAD65 DNA vaccine prevents insulitis, beta cell apoptosis and diabetes onset in NOD mice

PSN-9301 in combination with metformin improves glucose tolerance in two rat models of diabetes

Remicade now approved in U.S. for ulcerative colitis

New data on the efficacy and safety of indacaterol in asthma and COPD

Recent patents describe new analgesic agents

Novel anti-HIV agents reported by Kumamoto

Agents for thrombotic disorders in early development

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...